Vertex povetacicept faces scrutiny over infection risk ahead of Nov 30 FDA decision

Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk, according to STAT News.

Detected & updated continuously · Source: Nebula